Factive
(Gemifloxacin)ApprovedSmall molecule
Factive is one of 46 small molecule programs targeting Gonorrhea. It is currently in Approved.
3
Indications
4
Total Trials
1
Active Trials
45
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
59 competitors in Peritonitis
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Doribax
ShionogiApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Experimental
BiogenApproved
Eraxis
VVicuron Pharmaceuticals
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Chibroxin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Approved
Xifaxan
SSalix
Phase 3
Factive
LLG Chem
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Peritonitis1 trial
Gonorrhea1 trial
Efficacy of Combination Therapies for Gonorrhea Treatment
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00926796·614 enrolled
Rhinoscleroma1 trial
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
Unknown status·—·Phase 1·NCT03326050·60 enrolled
Regulatory
FDA Approval Timeline[4]
Apr 4, 2003
FACTIVE
NDA NDA021158
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]